Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Irish pharmaceutical firm Actavis has introduced a generic version of Celebrex (celecoxib) 50mg, 100mg, 200mg and 400mg capsules, as part of a settlement agreement with Pfizer.
Subscribe to our email newsletter
Celebrex is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis as well as for the management of acute pain in adults.
According to IMS Health data, for the 12-month period ending 30 June 2014, Celebrex had US sales of about $2.4bn.
In November 2014, the company agreed to acquire Botox-maker Allergan in a cash-and-stock deal that could be worth about $66bn, or $219 per Allergan share.
As part of that deal, Allergan investors would receive $129.22 in cash and 0.3683 Actavis shares for each share of the Botox-maker’s common stock.
The company is focused in developing and manufacturing generic, brand, branded generic, legacy brands and over-the-counter (OTC) pharmaceutical products and has commercial operations in about 60 countries.
It also develops new medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.